HK Stock Market Move | QYUNS-B(02509) rose by over 9% in early trading. QX029N recently received clinical approval. QX030N previously reached international authorization cooperation.

QYUNS-B(02509) rose more than 9% in early trading, and as of the time of publication, it rose by 7.49% to HK$16.64 with a trading volume of HK$9.4585 million. In terms of news, recently, Quanxinbiotech's new drug QX029N injection was approved for clinical trials, aiming to develop a treatment for adults with moderate to severe atopic dermatitis. In addition, Quanxinbiotech announced in April this year that it has reached an authorization partnership with Caldera Therapeutics. Caldera has obtained exclusive global development and commercialization rights for QX030N, while Quanxinbiotech has received a one-time prepayment of $10 million, approximately 24.88% of Caldera's equity, and potential additional payments of up to $545 million and royalties on sales under certain conditions. Furthermore, Quanxinbiotech achieved a revenue of RMB 159 million in 2024, with a net loss narrowing by 32.92% year-on-year. The company had previously stated in its 2024 performance meeting that Sailexin, as a biosimilar drug, has automatically entered the medical insurance directory. With the addition of Huadong Medicine's strong sales capabilities, it is expected that the sales of this product will reach RMB 300 million in 2025, peaking at RMB 1.5 billion to RMB 2 billion. Once the product generates sales profits, the share obtained by Quanxinbiotech will be included in the company's revenue.